Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Long-Term Prognosis and Transition Period until Progression in Fibrotic Hypersensitivity Pneumonitis.

Created on 18 Nov 2026

Authors

María Florencia Pilia, David Espejo, Irene Sansano, Christian Romero, Marta Andreu-Casas, Antia Ferreiro-Posse, Ana Villar, María Jesús Cruz, Xavier Muñoz, Iñigo Ojanguren

Published in

Respiration; international review of thoracic diseases. Volume 105. Issue 10. Pages 1063-1073. Nov 17, 2026.

Abstract

Hypersensitivity pneumonitis (HP) is an interstitial lung disease that may present as fibrotic (fHP) or non-fibrotic (nfHP). Fibrosis is associated with progression and poor outcomes; however, the transition to progressive pulmonary fibrosis (PPF) and its predictors remain unclear.
We retrospectively reviewed adult patients diagnosed with HP at a tertiary hospital (2010 and 2022). Patients were classified as having fHP or nfHP and were followed up for at least 1 year. Clinical, functional, radiological, and histological variables were analyzed. PPF was defined according to the 2022 clinical practice guideline of the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Asociación Latinoamericana de Tórax (ALAT).
Of 298 HP patients, 191 were included (153 fHP and 38 nfHP). Among patients with fHP, 76 (49.7%) developed PPF after a median of 3.2 years. Median survival was 4.8 years in fHP with PPF versus 6.3 years without, with 1.6 years from PPF onset to death or transplantation. The independent predictors of PPF and survival were lower forced vital capacity, elevated lactate dehydrogenase, fibroblastic foci, and microscopic honeycombing.
Nearly half of fHP patients progressed to PPF within a few years, with markedly reduced survival. Early recognition of high-risk patients may support timely antifibrotic treatment and improve outcomes.

PMID:
43044048
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement